Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its fourth quarter and fiscal year 2025 financial results announcement for August 7, 2025, after market close.
The company will host a webcast at 4:30 p.m. Eastern Time featuring senior management discussion of the results. The webcast will be accessible through Lifecore's investor relations website, with a replay available for 30 days following the live presentation.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione di sviluppo e produzione a contratto (CDMO), ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno fiscale 2025 per il 7 agosto 2025, dopo la chiusura del mercato.
L'azienda terr脿 una webcast alle 16:30 ora orientale con la partecipazione del management senior che discuter脿 i risultati. La webcast sar脿 accessibile tramite il sito web delle relazioni con gli investitori di Lifecore, con una replica disponibile per 30 giorni dopo la presentazione in diretta.
Lifecore Biomedical (NASDAQ: LFCR), una organizaci贸n de desarrollo y fabricaci贸n por contrato (CDMO), ha programado el anuncio de sus resultados financieros del cuarto trimestre y del a帽o fiscal 2025 para el 7 de agosto de 2025, despu茅s del cierre del mercado.
La compa帽铆a realizar谩 una transmisi贸n en vivo a las 4:30 p.m. hora del este, donde la alta direcci贸n discutir谩 los resultados. La transmisi贸n estar谩 disponible en el sitio web de relaciones con inversionistas de Lifecore, con una repetici贸n accesible durante 30 d铆as despu茅s de la presentaci贸n en vivo.
Lifecore Biomedical (NASDAQ: LFCR)電� 瓿勳暯 臧滊皽 氚� 鞝滌“ 臁办(CDMO)鞙茧, 2025 須岅硠鞐半弰 4攵勱赴 氚� 鞐瓣皠 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 7鞚� 鞛� 毵堦皭 頉勳棎 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
须岇偓电� 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 30攵�鞐� 瓴届榿歆勳澊 鞁れ爜鞚� 雲检潣頃橂姅 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞗轨簮鞀ろ姼電� Lifecore 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戩啀頃� 靾� 鞛堨溂氅�, 靸濎瓿� 頉� 30鞚缄皠 雼れ嫓氤搓赴 靹滊箘鞀り皜 鞝滉车霅╇媹雼�.
Lifecore Biomedical (NASDAQ : LFCR), une organisation de d茅veloppement et de fabrication sous contrat (CDMO), a programm茅 l'annonce de ses r茅sultats financiers du quatri猫me trimestre et de l'exercice 2025 pour le 7 ao没t 2025, apr猫s la cl么ture du march茅.
La soci茅t茅 organisera une webdiffusion 脿 16h30 heure de l'Est avec une pr茅sentation des r茅sultats par la direction. La webdiffusion sera accessible via le site des relations investisseurs de Lifecore, avec un replay disponible pendant 30 jours apr猫s la diffusion en direct.
Lifecore Biomedical (NASDAQ: LFCR), ein Auftragsentwicklungs- und Fertigungsunternehmen (CDMO), hat die Bekanntgabe der Finanzergebnisse f眉r das vierte Quartal und das Gesch盲ftsjahr 2025 f眉r den 7. August 2025 nach B枚rsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, bei dem das obere Management die Ergebnisse erl盲utert. Das Webcast ist 眉ber die Investor-Relations-Website von Lifecore zug盲nglich, und eine Aufzeichnung wird f眉r 30 Tage nach der Live-Pr盲sentation verf眉gbar sein.
- None.
- None.
Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern
CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (鈥淟ifecore鈥�), a fully integrated contract development and manufacturing organization (鈥淐DMO鈥�), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore鈥檚 senior management team will host a webcast to discuss the results.
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore鈥檚 website at: . Following the live webcast, an archived version of the webcast will be available on the company鈥檚 website for 30 days.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore鈥檚 website at .
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 [email protected] Tim Brons (Media) 415-675-7402 [email protected] Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 [email protected]
FAQ
When will Lifecore Biomedical (LFCR) report Q4 and FY 2025 earnings?
What time is Lifecore Biomedical's Q4 2025 earnings call?
How can I access Lifecore Biomedical's Q4 2025 earnings webcast?
How long will Lifecore Biomedical's Q4 2025 earnings webcast be available?
